Catalist

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

Monday, November 29, 2021 - 2:00pm

Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

Key Points: 
  • Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").
  • Eddy Lee, Chairman and CEO of iX Biopharma, said: "We are delighted to collaborate with Seelos Therapeutics, whose deep insights in ketamine drug development make them an ideal partner to further the development of Wafermine and the other sublingual ketamine products.
  • iX Biopharma will retain exclusive rights to Wafermine in China (including Hong Kong, Macau and Taiwan).
  • Other than Wafermine, iX Biopharma's portfolio includes among others, medicinal cannabis, sildenafil and buprenorphine sublingual wafers.

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

Wednesday, November 24, 2021 - 5:28pm

Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

Key Points: 
  • Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").
  • Eddy Lee, Chairman and CEO of iX Biopharma, said: "We are delighted to collaborate with Seelos Therapeutics, whose deep insights in ketamine drug development make them an ideal partner to further the development of Wafermine and the other sublingual ketamine products.
  • iX Biopharma will retain exclusive rights to Wafermine in China (including Hong Kong, Macau and Taiwan).
  • Other than Wafermine, iX Biopharma's portfolio includes among others, medicinal cannabis, sildenafil and buprenorphine sublingual wafers.

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

Wednesday, November 24, 2021 - 1:16pm

The US Food and Drug Administration (FDA) has granted Wafermine Orphan Drug designation for the treatment of CRPS.

Key Points: 
  • The US Food and Drug Administration (FDA) has granted Wafermine Orphan Drug designation for the treatment of CRPS.
  • Our team is very excited to be developing both acute, in SLS-002, and a potentially chronic, in SLS-003, ketamine-based therapy programs.
  • "We are delighted to collaborate with Seelos Therapeutics, whose deep insights in ketamine drug development make them an ideal partner to further the development of Wafermine and the other sublingual ketamine products," said Eddy Lee, Chairman and CEO of iX Biopharma.
  • We are therefore excited that this commercially significant agreement with Seelos is a validation of our ability to deliver on this strategy."

Don Agro International achieves 8.9 thousand tonnes growth in crops harvested, driven by land bank acquisitions and implementation of innovative technologies

Wednesday, November 24, 2021 - 2:00am

A key driving force which has enabled Don Agro to sustain this growth has been the expansion of the Group's totalled controlled land bank via new strategic acquisitions.

Key Points: 
  • A key driving force which has enabled Don Agro to sustain this growth has been the expansion of the Group's totalled controlled land bank via new strategic acquisitions.
  • With an arable land bank of approximately 3,200 hectares, Rav Agro Rost alone contributed up to 3.1 thousand tonnes of winter wheat and 1.54 thousand tonnes of sunflower.
  • Mr. Devlet-Kildeyev also added that the Group is applying a variety of innovative technologies to raise crops yields and productivity for Don Agro.
  • The Group also employs no-till farming technologies for up to 7.5 thousand hectares of its arable land bank at present.

Q&M Dental net profit surges 154% to S$35.4M for nine months ended 30 September 2021

Thursday, November 11, 2021 - 5:00am

The Group's net profit after tax increased by 154% to S$35.4 million from S$13.9 million in the previous period.

Key Points: 
  • The Group's net profit after tax increased by 154% to S$35.4 million from S$13.9 million in the previous period.
  • The Group's net profit after tax increased by 175% to S$13.9 million, from S$5.1 million in the previous period.
  • As at 30 September 2021, the Group's number of dental clinics in Singapore has grown to 90, from 81 as at 30 September 2020.
  • Q&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.

Hatten Land Forms Renewable Energy JV with Nestcon Berhad; Solar Panels to Install at Melaka's Largest Mall will Enable Solar Power for Digital and Blockchain Activities

Wednesday, November 10, 2021 - 12:00am

SGX Catalist-listed Hatten Land (the "Company", and together with its subsidiaries, the "Group")'s wholly-owned subsidiary, Hatten Renewable Energy Sdn.

Key Points: 
  • SGX Catalist-listed Hatten Land (the "Company", and together with its subsidiaries, the "Group")'s wholly-owned subsidiary, Hatten Renewable Energy Sdn.
  • ("Hatten Renewable Energy") has signed a joint-venture agreement ("JVA") with Nestcon Sustainable Solutions Sdn.
  • The JVA follows the Group's announcement in September 2021 that it had formed a strategic partnership with Nestcon for solar energy activities.
  • The JVA is part of a strategic pivot undertaken by Hatten Land to re-purpose its malls in Malaysia for digital and blockchain activities including cryptocurrency mining enabled by renewable energy.

Hatten Land Forms Joint Venture with Singapore Fintech Group Hydra X to Develop and Operate Cryptocurrency Exchanges in Singapore and Malaysia Focused on "Green" and "Clean" Cryptocurrencies and Tokens

Monday, November 1, 2021 - 1:00am

Ltd. ("Hatten Technology") has signed a joint venture agreement ("JVA") with homegrown fintech company HydraX Pte.

Key Points: 
  • Ltd. ("Hatten Technology") has signed a joint venture agreement ("JVA") with homegrown fintech company HydraX Pte.
  • Ltd. ("Hydra X") to establish a joint venture company ("JVC") to jointly develop and operate 'first-of-its-kind' cryptocurrency exchanges ("Crypto Exchanges") in Singapore and Malaysia.
  • Dato' Colin Tan, Executive Chairman and Managing Director of Hatten Land, said: "This joint venture to develop and operate Crypto Exchanges is strategic to our digital and blockchain initiatives.
  • Hatten Land Limited is one of the leading property developers in Malaysia specialising in integrated residential, hotel and commercial developments.

Entry into 3-Year Lease for an Industrial Property in Singapore to Commence Production of Lab-Grown Diamonds

Tuesday, October 19, 2021 - 2:32pm

Ltd. ("AET") has entered into a 3-year lease agreement for an industrial property located at Kallang for the production of lab-grown diamonds.

Key Points: 
  • Ltd. ("AET") has entered into a 3-year lease agreement for an industrial property located at Kallang for the production of lab-grown diamonds.
  • Diamonds are more widely known to be used in jewellery but diamonds are also commonly used for industrial applications in oil & gas, medical equipment, aerospace, among others.
  • There are also continual discoveries of greater uses for diamonds in industrial applications, which could herald future electronics with powerful new properties that will enable next-generation military, aerospace and telecommunications applications(1).
  • Building on our current momentum, we look forward to expand our production capabilities in Singapore and grow our business presence globally."

Hatten Land Signs Exclusive Framework Agreement with EnjinStarter to Digitise Group's Assets and Create New Digital Assets, including NFTs and Tokens Exchangeable with Current Loyalty Points Linked to its Malls and Hotels

Thursday, October 7, 2021 - 1:00am

SINGAPORE, Oct 7, 2021 - (ACN Newswire) - Hatten Land Limited ("Hatten Land") said today that its subsidiary Hatten Technology (S) Pte.

Key Points: 
  • SINGAPORE, Oct 7, 2021 - (ACN Newswire) - Hatten Land Limited ("Hatten Land") said today that its subsidiary Hatten Technology (S) Pte.
  • The Exclusive Framework Agreement is part of a strategic shift by SGX Catalist-listed Hatten Land.
  • Hatten Land is re-purposing its extensive mall footprint in Melaka and pivoting towards digital and blockchain activities as the pace of digitalisation in the world accelerates.
  • The initial term of the Exclusive Framework Agreement is two years and can be automatically renewed every two years unless the Agreement is terminated.

Aoxin Q & M acquires 49% stake in Acumen Diagnostics for S$29.4m

Monday, October 4, 2021 - 8:00am

- Aoxin Q & M acquires a stake in Acumen Diagnostics, one of the leading homegrown medical diagnostics and technology companies in Singapore

Key Points: 
  • - Aoxin Q & M acquires a stake in Acumen Diagnostics, one of the leading homegrown medical diagnostics and technology companies in Singapore
    - With Q & M holding a majority 51% stake in Acumen Diagnostics, the acquisition, upon completion, raises Q & M's total effective ownership in Acumen Diagnostics to 67.15%, based on Q & M's 32.95% equity stake in Aoxin Q & M
    - Acquisition will be immediately profit accretive; presents opportunity to assist in providing an essential capability to Singapore in this next phase of tackling the COVID-19 pandemic, as the availability of good quality test kits and testing services will be an important cog in the national response to treating and living with COVID-19
    SINGAPORE, Oct 4, 2021 - (ACN Newswire) - Aoxin Q & M Dental Group Ltd (SGX: 1D4.SI) ("Aoxin Q & M") and Q & M Dental Group (Singapore) Limited (SGX: QC7.SI) ("Q & M"), announced today that Aoxin Q & M will acquire 49% of Acumen Diagnostics Pte.
  • Q & M's total effective ownership of Acumen Diagnostics will thus amount to 67.15%, based on its 32.95% equity stake in Aoxin Q & M. See diagram 1 below.
  • The Board of Directors of Aoxin Q & M believes that the proposed acquisition will enhance the long-term interests of Aoxin Q & M and its shareholders.
  • Q & M supports this transaction, and this transaction is likely to be beneficial to Q & M and its shareholders and financially strengthen Q & M and Aoxin Q & M in the mid and long term."